A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multiple-Dose Study to Assess the Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
Phase of Trial: Phase II
Latest Information Update: 16 Aug 2017
At a glance
- Drugs NYX 2925 (Primary)
- Indications Neuropathic pain
- Focus Therapeutic Use
- Sponsors Aptinyx
- 01 Aug 2017 According to an Aptinyx media release, first patient has been randomized.
- 21 Jul 2017 Planned number of patients changed to 300.
- 13 Jul 2017 Status changed from planning to recruiting.